Monoclonal antibody ibalizumab maintains HIV suppression for nearly a decade
New once-a-week drug could be part of weekly oral treatment
Long-acting injectables work without oral lead-in period
Islatravir plus doravirine remains effective at 96 weeks
Injectable HIV therapy should save money if adherence is better than to oral therapies
“Unprecedented” case of transmission of four-class resistant HIV virus reported in France
Doravirine injections were safe and long-lasting, but did not reach therapeutic levels
Top 5 HIV treatment stories at AIDS 2020
Promising results for vesatolimod in monkeys and humans
